The Life Sciences team advised Royalty Pharma plc (Nasdaq: RPRX) in its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to $300 million in additional payments contingent on the achievement of certain sales milestones.
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
Trelegy is a combination of an inhaled corticosteroid and two bronchodilators in a single delivery device administered once-daily for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and the maintenance treatment of asthma in patients aged 18 years and older.
The Goodwin team was led by Jacqueline Mercier, Amarilice Young and Patrick O’Brien (Corporate), Robert Crawford, Sarah Stoiber and Alexandra Haas (Intellectual Property), Robert Carroll and Katerina Stavrianidis (IP Litigation), Jim Barri (Capital Markets & Debt Finance) and Paul Jin (Antitrust), with invaluable assistance from David Lopes (Paralegal).
For more details, read the press release and articles in The Deal and Seeking Alpha.